LXJDF could significantly ease IMQ-induced psoriasiform skin lesions embodied by the reduction of scaling, erythema, and infiltration, in addition to inhibiting epidermal hyperplasia (PCNA and Ki67), parakeratosis (loricrin), dermal inflammatory infiltration (CD3, CD4, F4/80, and CD11c), and epidermal lipid accumulation (LOX-1). This evidence concerns the gene LORICRIN and Erythema.